Physician profile
Charlene M Shero
NPI 1477634947
$1,664.27
in general payments reported to CMS, 2019-2025
10 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Geriatric Psychiatry provider received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $204 · 2023: $498 · 2024: $529 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,449 · Education: $10.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,449.24 |
| Education | $10.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $457.02 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $418.24 | 2022-2025 | Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $219.55 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $193.23 | 2022-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $104.19 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $102.73 | 2023-2025 | Vraylar |
| E.R. Squibb & Sons, L.L.C. | $78.28 | 2024 | Cobenfy |
| Lundbeck LLC | $41.25 | 2024-2025 | Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $30.27 | 2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $19.51 | 2023 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charlene Shero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.